Want to see GB:COG full AI Analyst Report?
Cambridge Cognition Holdings (COG) Share Price & Analysis
COG Stock Chart & Stats
- Day’s Range
- GBX 27.00 - GBX 27.00
- 52-Week Range
- GBX 26.60 - GBX 45.00
- Previous Close
- GBX 28.00
- Volume
- N/A
- Average Volume (3M)
- 13.40K
- Market Cap
- GBP 15.11M
- Enterprise Value
- GBP 15.04M
- Total Cash (Recent Filing)
- GBP 582.00K
- Total Debt (Recent Filing)
- GBP 239.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.05
- Next Earnings
- May 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
Consistently high gross margins indicate that the digital assessment offering has attractive underlying unit economics. If the company can control operating costs and rebuild revenue scale, this margin structure could support improved operating leverage and stronger future profitability.
Improved Balance Sheet
Material debt reduction alongside stronger equity improves financial resilience and lowers balance-sheet pressure. This gives Cambridge Cognition more flexibility to support its business, absorb operating volatility, and pursue development without the same level of leverage seen in 2023.
Specialized Digital Neuroscience Platform
Cambridge Cognition operates in a specialized area combining digital health and neuroscience, with tools covering attention, memory, and executive function. Its use across drug development, clinical trials, and healthcare creates multiple relevant applications for the same technology base.
Bears Say
Persistent Operating Losses
Four consecutive years of operating and net losses show that the current revenue base has not yet covered the company's cost structure. Persistent unprofitability can restrict reinvestment, weaken shareholder returns, and make sustainable earnings generation dependent on a meaningful improvement in operating efficiency.
Negative Free Cash Flow
Although cash burn improved substantially in 2025, free cash flow remained negative, meaning the business was still not self-funding. Continued cash consumption can limit the resources available for product development and may increase reliance on financing or balance-sheet resources.
Volatile Declining Revenue
Revenue remains well below the 2023 peak despite a small 3.8% increase in 2025, demonstrating limited and uneven growth momentum. A smaller revenue base makes fixed operating costs harder to absorb and increases the challenge of converting strong gross margins into lasting profitability.
Cambridge Cognition Holdings News
COG FAQ
What was Cambridge Cognition Holdings’s price range in the past 12 months?
What is Cambridge Cognition Holdings’s market cap?
When is Cambridge Cognition Holdings’s upcoming earnings report date?
How were Cambridge Cognition Holdings’s earnings last quarter?
Is Cambridge Cognition Holdings overvalued?
Does Cambridge Cognition Holdings pay dividends?
What is Cambridge Cognition Holdings’s EPS estimate?
How many shares outstanding does Cambridge Cognition Holdings have?
What happened to Cambridge Cognition Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cambridge Cognition Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cambridge Cognition Holdings
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Robert Baker
- Employees
- 74
- Website
- www.cambridgecognition.com
- Address
- Tunbridge Court, Cambridge, CAM, CB25 9TU, GB
Cambridge Cognition Holdings (COG) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 8 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 5 | 1 | 6 |







